JP2023523622A5 - - Google Patents
Info
- Publication number
- JP2023523622A5 JP2023523622A5 JP2022565707A JP2022565707A JP2023523622A5 JP 2023523622 A5 JP2023523622 A5 JP 2023523622A5 JP 2022565707 A JP2022565707 A JP 2022565707A JP 2022565707 A JP2022565707 A JP 2022565707A JP 2023523622 A5 JP2023523622 A5 JP 2023523622A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- nucleic acid
- transposase
- approximately
- myotis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026064617A JP2026099993A (ja) | 2020-04-29 | 2026-04-09 | 遺伝性黄斑変性症の治療のための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017442P | 2020-04-29 | 2020-04-29 | |
| US63/017,442 | 2020-04-29 | ||
| PCT/US2021/030007 WO2021222654A1 (en) | 2020-04-29 | 2021-04-29 | Compositions and methods for treatment of inherited macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026064617A Division JP2026099993A (ja) | 2020-04-29 | 2026-04-09 | 遺伝性黄斑変性症の治療のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023523622A JP2023523622A (ja) | 2023-06-06 |
| JP2023523622A5 true JP2023523622A5 (cg-RX-API-DMAC7.html) | 2024-05-15 |
Family
ID=78332210
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022565707A Pending JP2023523622A (ja) | 2020-04-29 | 2021-04-29 | 遺伝性黄斑変性症の治療のための組成物及び方法 |
| JP2026064617A Pending JP2026099993A (ja) | 2020-04-29 | 2026-04-09 | 遺伝性黄斑変性症の治療のための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026064617A Pending JP2026099993A (ja) | 2020-04-29 | 2026-04-09 | 遺伝性黄斑変性症の治療のための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230193319A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4142796A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023523622A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230004573A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115461082A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021265838A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175197A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL297718A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021222654A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4146798A4 (en) | 2020-05-04 | 2025-02-12 | Saliogen Therapeutics, Inc. | TRANSPOSITION-BASED THERAPIES |
| WO2023160454A1 (zh) * | 2022-02-25 | 2023-08-31 | 北京中因科技有限公司 | 表达盒组合及其应用 |
| EP4511496A4 (en) * | 2022-04-18 | 2026-06-24 | Abeona Therapeutics Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DOMINANT OPTIC ATROPHY AND X-RELATED RETINOSCHISISIS |
| CN120936710A (zh) * | 2023-02-02 | 2025-11-11 | 莱奥真生物科技有限公司 | 转座子系统的高活性转座酶蛋白及其用途 |
| KR102839746B1 (ko) * | 2023-04-27 | 2025-07-30 | 한국생명공학연구원 | 유전자의 망막 세포 내 발현을 위한 프로모터 및 이를 포함하는 벡터 시스템 |
| CN120230798A (zh) * | 2023-12-29 | 2025-07-01 | 上海朗昇生物科技有限公司 | 用于视网膜基因递送的重组腺相关病毒载体及其应用 |
| WO2025147466A1 (en) * | 2024-01-02 | 2025-07-10 | Alkeus Pharmaceuticals, Inc. | Treatment for asymptomatic stargardt disease patients |
| WO2025188836A1 (en) * | 2024-03-05 | 2025-09-12 | Saliogen Therapeutics, Inc. | Compositions and methods of using gene coding for treating ocular disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7309487B2 (en) * | 2004-02-09 | 2007-12-18 | George Inana | Methods and compositions for detecting and treating retinal diseases |
| US7943374B2 (en) * | 2005-08-21 | 2011-05-17 | Markus Hildinger | Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb |
| US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| KR20100097098A (ko) * | 2007-09-27 | 2010-09-02 | 리비젼 쎄러퓨틱스, 인크. | 레티놀 관련 질환을 치료하기 위한 방법 및 화합물 |
| US20090214478A1 (en) * | 2008-02-21 | 2009-08-27 | Alberto Auricchio | Method of treating ocular diseases by gene therapy |
| US20110311506A1 (en) * | 2009-02-25 | 2011-12-22 | The Johns Hopkins University | Piggybac transposon variants and methods of use |
| WO2013173637A1 (en) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating gene expression |
| DK2986635T3 (en) * | 2013-04-18 | 2019-01-28 | Fond Telethon | EFFECTIVE DELIVERY OF BIG GENES THROUGH DUAL-AAV VECTORS |
| WO2015139093A1 (en) * | 2014-03-21 | 2015-09-24 | The Sydney Children's Hospitals Network (Randwick And Westmead) (Incorporating The Royal Alexandra Hospital For Children) | Stable gene transfer to proliferating cells |
| JP7036723B2 (ja) * | 2015-12-14 | 2022-03-15 | コールド スプリング ハーバー ラボラトリー | 眼疾患の処置のための組成物および方法 |
| KR20200057051A (ko) * | 2017-09-27 | 2020-05-25 | 시질론 테라퓨틱스, 인크. | 활성 세포를 포함하는 방법, 조성물 및 이식 가능한 요소 |
| WO2020077360A1 (en) * | 2018-10-12 | 2020-04-16 | Poseida Therapeutics, Inc. | Hematopoietic stem cell compositions, methods of making and method of use |
-
2021
- 2021-04-29 CA CA3175197A patent/CA3175197A1/en active Pending
- 2021-04-29 EP EP21797217.3A patent/EP4142796A4/en active Pending
- 2021-04-29 IL IL297718A patent/IL297718A/en unknown
- 2021-04-29 AU AU2021265838A patent/AU2021265838A1/en active Pending
- 2021-04-29 WO PCT/US2021/030007 patent/WO2021222654A1/en not_active Ceased
- 2021-04-29 KR KR1020227039027A patent/KR20230004573A/ko not_active Ceased
- 2021-04-29 US US17/922,119 patent/US20230193319A1/en active Pending
- 2021-04-29 JP JP2022565707A patent/JP2023523622A/ja active Pending
- 2021-04-29 CN CN202180030798.2A patent/CN115461082A/zh active Pending
-
2026
- 2026-04-09 JP JP2026064617A patent/JP2026099993A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220387560A1 (en) | Adeno-Associated Virus-Mediated CRISPR-Cas9 Treatment of Ocular Disease | |
| US20230039928A1 (en) | Antisense oligonucleotides for nucleotide deamination in the treatment of Stargardt disease | |
| CA2904164C (en) | Mir-204 and mir-211 and uses thereof | |
| CN114829598A (zh) | 一种治疗Usher综合征的方法和其组合物 | |
| JP2022546597A (ja) | 閉端dnaおよび切断可能脂質を含む脂質ナノ粒子組成物ならびにそれらの使用方法 | |
| AU2020260154B2 (en) | Triple helix terminator for efficient RNA trans-splicing | |
| JP2002534353A (ja) | 高脂血症の遺伝子治療のための方法および化合物 | |
| CN108350446A (zh) | 基于crispr/cas9的治疗 | |
| JP2022521764A (ja) | Rho関連常染色体優性網膜色素変性症(adrp)を治療するためのcrispr/rna誘導ヌクレアーゼ関連の方法及び組成物 | |
| JP2023523622A (ja) | 遺伝性黄斑変性症の治療のための組成物及び方法 | |
| JP2025534371A (ja) | Opa1遺伝子変異に関連付けられる疾患を治療するためのopa1プレメッセンジャーrnaのトランススプライシングによる療法 | |
| JP2004532844A (ja) | イオントホレシスのステップを含む方法により送達されるキメラオリゴヌクレオチドでの遺伝子療法 | |
| JP7334346B2 (ja) | ロドプシン転写体に特異的なトランススプライシングリボザイム及びその用途 | |
| JP2025020293A (ja) | アンチセンスオリゴヌクレオチドは、abca4の異常スプライシングをレスキューする | |
| US20220305142A1 (en) | Ocular delivery of therapeutic agents | |
| CN116334141A (zh) | 基于基因编辑的RHO-R135W-adRP基因编辑药物 | |
| US20260007773A1 (en) | Ocular vectors and uses thereof | |
| CN120641085A (zh) | 包含核酸、可电离脂质、固醇、脂质锚定聚合物和辅助脂质的脂质纳米颗粒、其用途 | |
| RU2810907C1 (ru) | Система направленного изменения сплайсинга в гене MARK2 | |
| US20260137813A1 (en) | Genome editing methods and constructs | |
| JP2026516065A (ja) | シュタルガルト病を処置するためのデュアルaavベクター | |
| EP4619525A1 (en) | Methods for treating cep290 associated disease | |
| WO2024110770A1 (en) | A new promoter for retinal pigment epithelium (rpe) targeted gene therapy | |
| WO2026039524A1 (en) | Msh3 modulatory molecules | |
| Cardoso et al. | Nonviral Therapeutic Approaches for Modulation of Gene Expression: Nanotechnological Strategies to Overcome Biological Challenges |